This trial is evaluating whether Treatment will improve 2 primary outcomes, 1 secondary outcome, and 1 other outcome in patients with Genitourinary Cancers. Measurement will happen over the course of Two weeks.
This trial requires 20 total participants across 0 different treatment group
"In this cohort of patients with germ cell tumors, a significant proportion of the cancers were attributable to factors other than the genitostructure (primary cancer site), indicating the need to develop the proper treatment for local cancers. For cancers arising in the testis and ovary, the primary (genitostructural) site should be considered the standard treatment, not surgery." - Anonymous Online Contributor
"Urogenital neoplasms is a heterogenous disease involving both benign and malignant tumors. The prevalence of cancer is high, whereas malignancy is rare in females younger than 40 years of age. The most frequent site for cancers is the urinary tract. Histologically, most cancers are transitional cell carcinomas of the urinary tract. Urinary tract cancer can be divided into bladder, rectum and prostate cancer. As most common of cancers is transitional cell carcinoma of the bladder, more information on the biology and prevention must be investigated." - Anonymous Online Contributor
"Urogenital neoplasms are common. [Progression rates are less than previously reported] The incidence of urogenital neoplasms increases with age and has a female preponderance. [Falling incidence rates will make cancer control initiatives more attractive and accessible to a larger patient population." - Anonymous Online Contributor
"Neoplasms of the upper urinary tract cannot be cured. However, modern chemotherapy, immunotherapy, radiological techniques and urologic manipulation can reduce the effects on quality of life, but never cure the disease. It seems that complete remission can only be achieved in patients with inoperable or metastatic disease." - Anonymous Online Contributor
"Most urogenital cancers are treated with surgery, chemotherapy, radiation therapy, hormonal therapy, or a combination of these. More aggressive cancers frequently involve metastatic dissemination, which may require local or systemic therapies." - Anonymous Online Contributor
"Urogenital neoplasms may present with urinary tract symptoms, vaginal discharge, gynecological complaints or pelvic abnormalities. In particular, urinary tract symptoms in women or gynecological complaints in men may suggest a urogenital neoplasm. In contrast, symptoms suggestive of urinary tract infection and an inability to urinate are more strongly suggestive of urogenital malignancy than other types of symptoms." - Anonymous Online Contributor
"Radiation exposure appears to be the only predictor of grade toxicity following RT for anal cancer and urethral cancer. Most grade 3 or 4 pelvic-femoral-tibia or pelvic-femoral-pelvis toxicity is caused by high doses or poor organ positioning following RT. In particular, grade 4 or higher toxicity is uncommon following treatment of anal cancer and urethral cancer. Radiation doses are consistently associated with pelvic-femoral-pelvis or pelvic-femoral-tibia and pelvic-femoral-femoral toxicity following RT. Radiation doses ≤50 Gy are typically sufficient to control cancer, with less stringent treatment being safer than more aggressive treatment." - Anonymous Online Contributor
"Recent findings of this study suggest that urogenital epithelial neoplasms were caused by diverse factors, although the vast majority of cases were not associated with hereditary tumors, which could be attributable to lifestyle and environmental factors. When a primary neoplasm is present, it may influence prognosis and a more accurate classification in terms of risk of metastasis and therapeutic approach are necessary." - Anonymous Online Contributor
"As more trials are conducted on treatment for urogenital neoplasms, it is expected that treatment for these tumors will continue to evolve. Clinical trials can be an important resource for treating urogenital neoplasms because of the high level of patients seeking treatment for different urogenital neoplasms." - Anonymous Online Contributor
"The data support the hypothesis that UOGN occurrence may be associated with other familial cancers of the endocrine-metabolism apparatus. Furthermore, the results suggest that hereditary malignancies are associated with a significant increment in the risk of UOGN. Further studies with a larger sample size and longer follow-up periods are needed to confirm these results." - Anonymous Online Contributor
"We believe that this guideline is a valuable resource for pediatric urologist. It describes the approach to children with various urogenital masses. It provides helpful and comprehensive information. This guideline also contains a comprehensive list of treatment options that is easy to access for any pediatric urologist or treating physician." - Anonymous Online Contributor
"There has been many advances in the surgical field. The main goal of surgery is to take the cancer out while remaining as close to normal tissue as possible. There is still much to discover as well regarding surgery's role in oncology. The future may see new and improved treatment based on improved imaging techniques and improved instrumentation." - Anonymous Online Contributor